The SOPHiA DDM HRD Solution offers cost-effective, accurate,
reliable, timely, and easily implementable in-house results to
empower better clinical research decisions
BOSTON and LAUSANNE,
Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA
GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine,
announced today the launch of their SOPHiA DDM Homologous
Recombination Deficiency (HRD) Solution, opening new doors for
cancer research. The application provides a unique approach for
molecular cancer testing by combining the identification of
HRD-causing mutations with the analysis of HRD-induced genomic
instability across the whole genome of tumor samples.
![SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS) SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)](https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg)
HRD is caused by a cell's impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway and is linked with the development of certain
cancers. It is also an important predictor of tumor response to
treatment with PARP inhibitors. Molecular testing of tumor samples
using SOPHiA DDM enables simultaneous detection of both HRR
mutations that can cause HRD, including those in the BRCA1
and BRCA2 genes, and the accumulated damage to genomic
integrity that can result from them, using shallow whole-genome
Next Generation Sequencing.
SOPHiA GENETICS is collaborating with AstraZeneca, aiming to
expand access to in-house HRD testing across European laboratories
and institutions. "Providing laboratories with innovative solutions
to enable locally-delivered HRD testing is critically important,
particularly in settings such as advanced ovarian cancer, where
approximately half of all newly diagnosed patients have
HRD-positive tumors," said Kristina Rodnikova, SVP Global Oncology
Diagnostics at AstraZeneca. "We are pleased to work with SOPHiA
GENETICS in their mission to empower their laboratory customers and
increase the range of options available for HRD detection."
To combat current challenges with HRD detection offerings, the
SOPHiA DDM HRD Solution provides laboratories and institutions with
a decentralized approach to HRD testing for tumor samples. The
SOPHiA DDM HRD Solution allows the user to retain full ownership of
their data and save time and expenses, while also offering
comprehensive genomic insights powered by deep learning
algorithms.
"We at SOPHiA GENETICS have always been on a mission to improve
health outcomes by advancing data-driven medicine, which is
why I am extremely excited to announce the launch of our new HRD
research solution," said Dr. Jurgi Camblong, Co-founder and CEO of
SOPHiA GENETICS. "Our SOPHiA DDM HRD Solution will
provide researchers and other healthcare professionals with a
decentralized approach to fully integrated HRD testing, enabling
the HRD status of more advanced ovarian cancer cases to be
determined without reliance on send-out testing solutions."
To learn more about how SOPHiA GENETICS' data-driven insights
are improving diagnosis, treatment, and drug development for
patients and the larger medical community, visit
www.sophiagenetics.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
Information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenertics.com to obtain
the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-new-deep-learning-capabilities-to-support-the-detection-of-homologous-recombination-deficiencies-301489568.html
SOURCE SOPHiA GENETICS